Gabapentin enacarbil

USDailyMed:Gabapentin_enacarbilUSFDA:Horizant AU:B1 None US:℞-only (1-{[({(1RS)-1-[isobutyryloxy]ethoxy}carbonyl)amino]methyl}cyclohexyl)acetic acid 478296-72-9Y 9883933 7560 8059607N 75OCL1SPBQ CHEBI:68840N DTXSID30870359 Interactive image CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)NKey:TZDUHAJSIBHXDL-UHFFFAOYSA-NN Gabapentin enacarbil, sold under the brand nameHorizant, among others, is ananticonvulsantandanalgesicdrug of thega‍‍‍‍‍‍​​​‍​​​​​​bapentinoidclass, and aprodrugtogabapentin.It was designed for increased oralbioavailabilityover gabapentin,and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability,especially when taken with a fatty meal.Gabapentin enacarbil has passed humanclinical trialsfor the treatment ofrestless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective. Gabapentin enacarbil was denied approval by the USFood and Drug Administration(FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk.On 6 April 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome.On 7 June 2012, the FDA approved Horizant for the treatment ofpostherpetic neuralgiain adults.